Menactra® is a meningococcal A,C,Y,W-135 conjugate vaccine used to protect against four groups of Neisseria meningitidis, group A, group C, group Y and group W-135.
Menactra® is used as an alternative vaccine to the meningococcal C conjugate vaccines (Meningitec® and Neisvac-C™) and the meningococcal A,C,Y,W-135 polysaccharide vaccines (Menomune® ACYW-135 and Mencevax® ACYW).
The conjugate and polysaccharide vaccines work differently to generate protection against the bacteria. Protection from the conjugate vaccines lasts longer than that from the polysaccharide vaccines. The conjugate vaccines also generate long term memory cells allowing rapid boosting of immunity years later.
NeisVac-C™ is a menincococcal C conjugate vaccine used to protect against Neisseria meningitidis group C only.
The conjugate and polysaccharide vaccines work differently to generate protection against the bacteria. Protection from the conjugate vaccines lasts longer than that from the polysaccharide vaccines. The conjugate vaccines also generate long term memory cells allowing rapid boosting of immunity years later.
Meningitec® is a menincococcal C conjugate vaccine used to protect against Neisseria meningitidis group C only.
The conjugate and polysaccharide vaccines work differently to generate protection against the bacteria. Protection from the conjugate vaccines lasts longer than that from the polysaccharide vaccines. The conjugate vaccines also generate long term memory cells allowing rapid boosting of immunity years later.
Synflorix® is used for primary and booster vaccination of infants and children up to their 5th birthday to protect against disease caused by 10 types of streptococcus pneumoniae.
Prevenar 13® is used for primary and booster immunisation of infants and children and primary immunisation of adults at increased risk of pneumococcal disease to protect against disease caused by 13 types of Streptococcus pneumoniae.
The vaccine is licensed for use in infants and children up to their 5th birthday and for adults from 50 years of age. It is used out of licensure in children 5-16 years of age and adolescents/adults between 16-49 years of age as there is no alternative pneumococcal conjugate vaccine available in New Zealand for this age group. When the vaccine is administered to individuals between 5-49 years of age, use will be outside of current licensure. There are not expected to be any safety concerns for use in this age group.
Act-HIB™ is used for primary and booster vaccination of infants and children up to their 5th birthday to protect against disease caused by Haemophilus influenzae type b.The vaccine is also used for primary vaccination of children aged 5 years of age and over and adults with some chronic medical conditions. Act-HIB™ is licensed for use in infants and children 2 months to 5 years of age. It is used out of licensure in children 5 years of age and over and adults as there is no alternative vaccine available in New Zealand for these age groups. When children/individuals are older than the age to which the vaccine is licensed, use will be outside of current licensure. No safety concerns are expected for use in older age groups.
